
|Videos|December 13, 2021
Individuals With Chronic Lymphocytic Leukemia Benefit More From iFCR Therapy Than Older Individuals
Matthew Davids, MD, MMSc, associate professor of medicine at Harvard Medical School, discusses how the results of a longer term study differ for individuals who were younger with chronic lymphocytic leukemia as opposed to those who are older.
Advertisement
In a Pharmacy Times® Interview, Matthew Davids, MD, MMSc, associate professor of medicine at Harvard Medical School, discusses his oral presentation at ASH 2021 of the Longer Term Follow-up of a Multicenter, Phase 2 Study of Ibrutinib Plus Fludarabine, Cyclophosphamide, Rituximab (iFCR) As Initial Therapy for Younger Patients with Chronic Lymphocytic Leukemia (CLL).
He discussed how the results of a longer term study differ for individuals who were younger as opposed to those who are older.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Scrutiny of GLP-1 Compounding Is Just Getting Started, Expert Says
2
The Biosimilar Conversation Nobody Is Having at the Pharmacy Counter: Why Adoption Is Still Struggling and What We Can Do About It
3
Updated 2025-2026 COVID-19 Vaccine Nearly Halved ED Visits, Hospitalizations in CDC-Funded Study
4
FDA Accepts NDA for Giredestrant in Early-Stage ER-Positive Breast Cancer Under Priority Review
5


















































































































